Craniotomy and Endovascular Intracranial Procedures DRG Reimbursement

DRG 027 covers craniotomy and endovascular intracranial procedures without Major Complication or Comorbidity and without Complication or Comorbidity, encompassing surgical and endovascular treatments for intracranial conditions where no significant secondary diagnoses are present. This grouping matters for inpatient reimbursement because it establishes the standardized Medicare Severity Diagnosis-Related Group payment for uncomplicated cases and influences hospital payment for neurosurgical and neurointerventional services.

DRG 027 Overview

DRG 027 includes inpatient hospital admissions for craniotomy and endovascular intracranial procedures without a Major Complication or Comorbidity and without a Complication or Comorbidity. It typically covers surgical or endovascular treatment of intracranial pathology such as tumor resection, vascular malformation repair, or aneurysm clipping/coiling when no significant secondary diagnoses increase resource use. This Diagnosis-Related Group matters for Medicare payment because it groups clinically similar cases with expected comparable resource consumption and establishes the base payment for uncomplicated procedures. Accurate clinical coding and documentation determine assignment to this Diagnosis-Related Group and thereby affect inpatient reimbursement.

Acute procedural efficacy and safety trials evaluating minimally invasive techniques for intracranial hemorrhage evacuation or aneurysm repair: These studies enroll adult patients undergoing craniotomy or endovascular intracranial procedures for acute aneurysmal subarachnoid hemorrhage, symptomatic intracerebral hemorrhage, or ruptured vascular lesions, comparing novel operative approaches, intraoperative imaging adjuncts, or peri‑procedural management protocols to standard practice. They measure perioperative neurological outcomes, complication rates (rebleeding, vasospasm, ischemia), and short‑term functional status, which directly informs surgeons and payers about procedural risk profiles, length of stay drivers, and immediate resource utilization for patients classified under this DRG.
Comparative effectiveness research contrasting open craniotomy versus endovascular approaches for elective cerebrovascular lesions: These observational cohort studies or pragmatic randomized trials target patients with unruptured aneurysms, arteriovenous malformations, or symptomatic stenotic intracranial lesions to determine differences in clinical outcomes, reintervention rates, and cost‑effectiveness between modalities. Findings guide provider decision‑making about procedure selection, inform bundled payment strategies, and help payers and hospitals anticipate downstream costs such as ICU utilization and readmissions associated with each approach.
Post‑discharge outcomes and rehabilitation trials focused on functional recovery and readmission reduction after intracranial procedures: These studies follow patients discharged after craniotomy or endovascular intracranial interventions to test care‑transition interventions, tailored neurorehabilitation programs, or remote monitoring to improve 30‑ and 90‑day functional outcomes, minimize complications like wound infection or delayed hydrocephalus, and reduce avoidable readmissions. Results are relevant to inpatient case managers and payers because they identify interventions that shorten overall episode cost, improve quality metrics (functional independence, discharge disposition), and lower post‑acute care utilization for this DRG.

Acute procedural efficacy and safety trials evaluating minimally invasive techniques for intracranial hemorrhage evacuation or aneurysm repair: These studies enroll adult patients undergoing craniotomy or endovascular intracranial procedures for acute aneurysmal subarachnoid hemorrhage, symptomatic intracerebral hemorrhage, or ruptured vascular lesions, comparing novel operative approaches, intraoperative imaging adjuncts, or peri‑procedural management protocols to standard practice. They measure perioperative neurological outcomes, complication rates (rebleeding, vasospasm, ischemia), and short‑term functional status, which directly informs surgeons and payers about procedural risk profiles, length of stay drivers, and immediate resource utilization for patients classified under this DRG.
Comparative effectiveness research contrasting open craniotomy versus endovascular approaches for elective cerebrovascular lesions: These observational cohort studies or pragmatic randomized trials target patients with unruptured aneurysms, arteriovenous malformations, or symptomatic stenotic intracranial lesions to determine differences in clinical outcomes, reintervention rates, and cost‑effectiveness between modalities. Findings guide provider decision‑making about procedure selection, inform bundled payment strategies, and help payers and hospitals anticipate downstream costs such as ICU utilization and readmissions associated with each approach.
Post‑discharge outcomes and rehabilitation trials focused on functional recovery and readmission reduction after intracranial procedures: These studies follow patients discharged after craniotomy or endovascular intracranial interventions to test care‑transition interventions, tailored neurorehabilitation programs, or remote monitoring to improve 30‑ and 90‑day functional outcomes, minimize complications like wound infection or delayed hydrocephalus, and reduce avoidable readmissions. Results are relevant to inpatient case managers and payers because they identify interventions that shorten overall episode cost, improve quality metrics (functional independence, discharge disposition), and lower post‑acute care utilization for this DRG.

OpenPayer

Summary & Overview

Craniotomy and Endovascular Intracranial Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 027 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes